Market Access as a Driver of Biotech Value in 2026
How policy uncertainty, evidence expectations, and access strategy are shaping decisions earlier in the lifecycle.
Market access strategy in biopharma has always mattered. What has changed is how early it now influences strategic decisions.
During Magnolia Market Access’s January 2026 webinar, Decoding Market Access: A Critical Driver of Biotech Value, panelists discussed how policy uncertainty, payer evidence expectations, and pricing realities are shaping decisions well before launch. These forces are not diminishing the role of science and innovation; they are reshaping how innovation translates into sustained access and long-term value.
“Science and innovation will always be what drives our industry forward, but now you’re starting to see policy as something that can be influential beyond just the science and the innovation.”
— Sean McGonigal, VP, Growth, Magnolia Market Access
.
Market Access Is No Longer a Downstream Function
Market access cannot be treated as a reimbursement exercise confined to launch.
Instead, it reflects how policy, health economics, real-world evidence, pricing strategy, and payer decision-making intersect across the product lifecycle. This shift reflects a broader evolution in market access strategy in biopharma, where access considerations are increasingly embedded earlier in development planning.
This broader framing mirrors how access decisions are actually made and why late, siloed planning often leads to avoidable constraints. When access is treated as an integrated discipline rather than a downstream task, organizations gain clearer visibility into tradeoffs earlier, before expectations harden and options narrow.
Rather than focusing on any single regulation or proposal, uncertainty has become a defining feature of the access environment. Ongoing policy discussions, particularly around pricing and innovation incentives, are influencing how companies think about development strategy, launch sequencing, and long-term value.
At the same time, overreacting carries its own risks. Policy signals should inform scenario planning, not drive abrupt shifts that undermine development momentum and reverse strategic planning.
““Even when policies are still being discussed or modeled, they raise real questions that companies need to be thinking through early.”
— Tracy Baroni-Allmon, VP, Health Policy, Magnolia Market Access
Access Questions Are Appearing Earlier, Including with Investors
Another recurring theme was timing. Market access considerations are no longer confined to commercialization teams or pre-launch planning. Increasingly, they are part of earlier conversations with executive leadership and investors.
Assumptions around value and access are being examined earlier in development, particularly as companies navigate differences in access expectations across markets.
Decision-makers increasingly use access strategy, explicitly or implicitly, as a credibility test for how well a company understands the commercial reality it will face.
This shift places greater importance on aligning development, evidence, and access strategy early, before expectations are set internally or externally.
Evidence Strategy Must Anticipate How Decisions Are Made
Scientific rigor remains essential, but it is not sufficient to support access on its own. Too often, access considerations surface after critical design decisions have already been locked in.
Trial design, endpoint selection, and analytic approaches directly shape how payers and policymakers assess value.
Introducing access considerations earlier in development helps teams anticipate evidence gaps, pressure-test value narratives, and make more informed tradeoffs without unnecessary complexity.
“Strong science matters, but it doesn’t automatically translate into access. The real question is whether the evidence and value story hold up in real-world decision-making.”
— Amanda Forys, Managing Partner, Magnolia Market Access
Balancing Patients, Business, and Reputation
The discussion repeatedly returned to the challenge of balancing patient impact, business objectives, and reputational considerations, particularly in an environment where pricing and access decisions are closely scrutinized.
Judgment and timing have emerged as critical factors, particularly when resources are constrained and expectations are evolving.
“When you’re early in the development, think a little bit. When you’re closer to launch, think a lot.”
— Jim Coccia, Principal and Founder, TKG Access
In practice, this level of judgment depends on a clear understanding of who is actually expected to access the therapy. Knowing the payer mix early helps inform not only pricing and evidence strategy, but also decisions around launch sequencing, resourcing, and patient access pathways.
Right-sizing access planning to the stage of the asset helps preserve credibility while still preparing for future access challenges.
Market Access Is a Lifecycle Discipline
Rather than a single milestone, organizations should consider market access continuously, evolving alongside the asset as data, assumptions, and policy conditions change. A lifecycle-oriented approach to market access strategy helps biopharma organizations adapt as policy, evidence, and payer expectations evolve.
Organizations that revisit access strategies over time, rather than treating it as a one-time exercise, are better positioned to adapt without losing momentum or credibility.
Key Takeaways for Biopharma Leaders
The Bottom Line
Today, market access strategy plays a central role in shaping development decisions, investor confidence, and long-term value. Meeting these demands requires integrated thinking across policy, evidence, pricing, and access strategy throughout the product lifecycle.
Watch the on-demand webinar on market access and biotech value.
Magnolia Market Access partners with biopharma organizations to turn policy signals into clear access strategy and planning framework. Contact us to align policy, evidence, and access strategy earlier in the lifecycle.